Triple-Negative Breast Cancer
Toripalimab regimen delays progression of PD-L1-positive triple-negative breast cancer
CHICAGO — The addition of toripalimab to first-line nab-paclitaxel significantly prolonged PFS among patients with PD-L1-positive metastatic or recurrent triple-negative breast cancer, according to results of a phase 3 trial.
Sizable state variations in racial, ethnic disparities for triple-negative breast cancer
A cohort study published in JAMA Oncology found substantial state variations in racial and ethnic disparities in triple-negative breast cancer incidence, with Black women in four states having the highest rates.
Study of vaccine for triple-negative breast cancer moves into next phase
Researchers at Cleveland Clinic intend to expand their study of a novel vaccine designed to prevent triple-negative breast cancer.
Oncolytic virus therapy may boost antitumor response in triple-negative breast cancer
The oncolytic virus talimogene laherparepvec combined with neoadjuvant chemotherapy appeared safe and effective for women with early-stage triple-negative breast cancer, according to phase 2 study results published in Nature Medicine.
Carboplatin regimen extends EFS in triple-negative breast cancer
SAN ANTONIO — The addition of carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy significantly improved outcomes among patients with triple-negative breast cancer, according to study results.
UNC professor receives distinguished lectureship in breast cancer research
Charles M. Perou, PhD, received the 2022 AACR Distinguished Lectureship in Breast Cancer Research at this year’s San Antonio Breast Cancer Symposium.
Practice-changing treatment advances continue in early-stage triple-negative breast cancer
The treatment landscape for early-stage triple-negative breast cancer continues to evolve, according to a speaker at Chemotherapy Foundation Symposium.
Breast Cancer Awareness Month: New insights to guide survivorship care
Breast Cancer Awareness Month is observed every October.
Novel bispecific T-cell receptor therapy shows early promise in advanced solid tumors
An off-the-shelf T-cell receptor therapy has shown promising early results in multiple solid tumor types, according to initial data from a phase 1 dose-escalation trial presented at ESMO Congress.
Neoadjuvant immunotherapy effective regardless of race in triple-negative breast cancer
Results of a phase 1/phase 2 study showed similar treatment outcomes among Black and non-Black women who received durvalumab plus chemotherapy prior to surgery for triple-negative breast cancer.